Enovis Corporation (ENOV) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 13 analysts103.7% Below Target
ENOV trades 103.7% below Wall Street's consensus target of $44.75.
Current Price$21.97
Average Target$44.75
Target
Current
Low$36.00
Median$45.50
High$52.00
Analyst Target Range
Forward P/E6.0x
(Value)
PEG Ratio—
Implied Growth+118.2%
(High Growth)
Analyst Spread35.8%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes ENOV achieves its forward estimates and maintains a stable P/E multiple of 6.0x. This scenario reflects the blended consensus of 13 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
ENOV Price Target Analysis
Updated June 21, 2026As of June 21, 2026, Enovis Corporation (ENOV) has a Wall Street consensus price target of $44.75, based on estimates from 13 covering analysts. With the stock currently trading at $21.97, this represents a potential upside of +103.7%. The company has a market capitalization of $1.26B.
Analyst price targets range from a low of $36.00 to a high of $52.00, representing a 36% spread in expectations. The median target of $45.50 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 10 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ENOV trades at a trailing P/E of -1.1x and forward P/E of 6.0x. Analysts expect EPS to grow +118.2% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Industrials stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+52.0%
Industry Consensus
Avg Forward P/E
129.3x
(High Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 NVCRNovoCure Limited | $1.6B | $14.28 | $33.00 | +131.1% | Buy | — | 15 |
 INVAInnoviva, Inc. | $1.7B | $22.49 | $37.00 | +64.5% | Buy | 6.3x | 10 |
 LMATLeMaitre Vascular, Inc. | $2.1B | $93.95 | $127.50 | +35.7% | Buy | 31.3x | 20 |
 ATRCAtriCure, Inc. | $1.5B | $28.80 | $51.33 | +78.2% | Buy | 768.0x | 19 |
 ZBHZimmer Biomet Holdings, Inc. | $17.2B | $87.97 | $96.33 | +9.5% | Hold | 10.4x | 42 |
 SNNSmith & Nephew plc | $12.8B | $30.08 | $30.93 | +2.8% | Hold | 13.6x | 22 |
 GMEDGlobus Medical, Inc. | $10.7B | $79.23 | $109.50 | +38.2% | Buy | 16.7x | 36 |
 OFIXOrthofix Medical Inc. | $382M | $9.45 | $15.60 | +65.1% | Hold | — | 17 |
 AORTArtivion, Inc. | $1.0B | $21.19 | $40.50 | +91.1% | Buy | 171.2x | 12 |
ENOV — Frequently Asked Questions
Quick answers to the most common questions about buying ENOV stock.
What is the ENOV stock price target for 2026?
The consensus Wall Street price target for ENOV is $44.75, representing 103.7% upside from the current price of $21.97. With 13 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is ENOV a buy, sell, or hold?
ENOV has a consensus rating of "Buy" based on 13 Wall Street analysts. The rating breakdown is predominantly bullish, with 10 Buy/Strong Buy ratings. The consensus 12-month price target of $44.75 implies 103.7% upside from current levels.
Is ENOV stock overvalued or undervalued?
With a forward P/E of 6.025x, ENOV trades at a relatively low valuation. The consensus target of $44.75 implies 103.7% appreciation, suggesting meaningful undervaluation.
How high can ENOV stock go?
The most bullish Wall Street analyst has a price target of $52 for ENOV, while the most conservative target is $36. The consensus of $44.75 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover ENOV stock?
ENOV is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 10 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the ENOV stock forecast?
The 12-month ENOV stock forecast based on 13 Wall Street analysts shows a consensus price target of $44.75, with estimates ranging from $36 (bear case) to $52 (bull case). The median consensus rating is "Buy".
What is ENOV's forward P/E ratio?
ENOV trades at a forward P/E ratio of 6.0x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy ENOV stock?
Wall Street analysts are very optimistic on ENOV, with a "Buy" consensus rating and $44.75 price target (103.7% upside). 10 of 13 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do ENOV price targets vary so much?
ENOV analyst price targets range from $36 to $52, a 36% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $44.75 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare